Franciska Lebbink

Ms. Franciska Lebbink

DKFZ, Heidelberg, Baden-Württemberg, Germany
+2
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FLFranciska Lebbink
Franciska Lebbink
MSMarkus Stock
Markus Stock
Dietmar GeorgDietmar Georg
Dietmar Georg
BKBarbara Knäusl
Barbara Knäusl
Motion amplitudes, in need of mitigation for moving targets irradiated with pulsed carbon ions and protons, were identified to guide the decision on treatment and motion mitigation strategy. Measurements with PinPoint ionisation chambers positioned in an anthropomorphic breathing phantom were acquired to investigate different tumour motion scenarios, including rib and lung movements. The effect of beam delivery dynamics and spot characteristics was considered. The dose in the tumour centre was deteriorated up to 10% for carbon ions but only up to 5% for protons. Dose deviations in the penumbra increased by a factor of two when comparing carbon ions to protons, ranging from 2 to 30% for an increasing motion amplitude that was strongly dependent on the beam intensity. Layer rescanning was able to diminish the dose distortion caused by tumour motion, but an increase in spot size could reduce it even further to 5% within the target and 10% at the penumbra. An increased need for motion mitigation of carbon ions compared to protons was identified to assure target coverage and sparing of adjacent organs at risk in the penumbra region and outside the target. For the clinical implementation of moving target treatments at a synchrotron-based particle facility complex, time dependencies needed to be considered.

5 June 2021 in Medical Physics
Verified
Journal Article
Open access
PDF file
EFEmmanuelle Fleury
Emmanuelle Fleury
PTPetra Trnková
Petra Trnková
KSKees Spruijt
Kees Spruijt
JHJoël Herault
Joël Herault
FLFranciska Lebbink
Franciska Lebbink
MHMischa Hoogeman
Mischa Hoogeman
Purpose: Eye‐dedicated proton therapy (PT) facilities are used to treat malignant intraocular lesions, especially uveal melanoma (UM). The first commercial ocular PT beamline from Varian was installed in the Netherlands. In this work, the conceptual design of the new eyeline is presented. In addition, a comprehensive comparison against five PT centers with dedicated ocular beamlines is performed, and the clinical impact of the identified differences is analyzed.Material/Methods: The HollandPTC eyeline was characterized. Four centers in Europe and one in the United States joined the study. All centers use a cyclotron for proton beam generation and an eye‐dedicated nozzle. Differences among the chosen ocular beamlines were in the design of the nozzle, nominal energy, and energy spectrum. The following parameters were collected for all centers: technical characteristics and a set of distal, proximal, and lateral region measurements. The measurements were performed with detectors available in‐house at each institution. The institutions followed the International Atomic Energy Agency (IAEA) Technical Report Series (TRS)‐398 Code of Practice for absolute dose measurement, and the IAEA TRS‐398 Code of Practice, its modified version or International Commission on Radiation Units and Measurements Report No. 78 for spread‐out Bragg peak normalization. Energy spreads of the pristine Bragg peaks were obtained with Monte Carlo simulations using Geant4. Seven tumor‐specific case scenarios were simulated to evaluate the clinical impact among centers: small, medium, and large UM, located either anteriorly, at the equator, or posteriorly within the eye. Differences in the depth dose distributions were calculated.Results: A pristine Bragg peak of HollandPTC eyeline corresponded to the constant energy of 75 MeV (maximal range 3.97 g/cm2 in water) with an energy spread of 1.10 MeV. The pristine Bragg peaks for the five participating centers varied from 62.50 to 104.50 MeV with an energy spread variation between 0.10 and 0.70 MeV. Differences in the average distal fall‐offs and lateral penumbrae (LPs) (over the complete set of clinically available beam modulations) among all centers were up to 0.25 g/cm2, and 0.80 mm, respectively. Average distal fall‐offs of the HollandPTC eyeline were 0.20 g/cm2, and LPs were between 1.50 and 2.15 mm from proximal to distal regions, respectively. Treatment time, around 60 s, was comparable among all centers. The virtual source‐to‐axis distance of 120 cm at HollandPTC was shorter than for the five participating centers (range: 165–350 cm). Simulated depth dose distributions demonstrated the impact of the different beamline characteristics among institutions. The largest difference was observed for a small UM located at the posterior pole, where a proximal dose between two extreme centers was up to 20%.Conclusions: HollandPTC eyeline specifications are in accordance with five other ocular PT beamlines. Similar clinical concepts can be applied to expect the same high local tumor control. Dosimetrical properties among the six institutions induce most likely differences in ocular radiation‐related toxicities. This interinstitutional comparison could support further research on ocular post‐PT complications. Finally, the findings reported in this study could be used to define dosimetrical guidelines for ocular PT to unify the concepts among institutions.

13 January 2021 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
LHLinda Heskamp
Linda Heskamp
FLFranciska Lebbink
Franciska Lebbink
MUMark J. van Uden
Mark J. van Uden
MMMarnix C. Maas
Marnix C. Maas
JCJurgen A. H. R. Claassen
Jurgen A. H. R. Claassen
AHArend Heerschap
Arend Heerschap
Key points: The post‐exercise recovery of phosphocreatine, a measure of the oxidative capacity of muscles, as assessed by 31P MR spectroscopy, shows a striking increase from distal to proximal along the human tibialis anterior muscle. To investigate why this muscle exhibits a greater oxidative capacity proximally, we tested whether the spatial variation in phosphocreatine recovery rate is related to oxygen supply, muscle fibre type or type of exercise. We revealed that oxygen supply also increases from distal to proximal along the tibialis anterior, and that it strongly correlated with phosphocreatine recovery. Carnosine level, a surrogate measure for muscle fibre type was not different between proximal and distal, and type of exercise did not affect the gradient in phosphocreatine recovery rate. Taken together, the findings of this study suggest that the post‐exercise spatial gradients in oxygen supply and phosphocreatine recovery are driven by a higher intrinsic mitochondrial oxidative capacity proximally. Phosphorus magnetic resonance spectroscopy (31P MRS) of human tibialis anterior (TA) revealed a strong proximo‐distal gradient in the post‐exercise phosphocreatine (PCr) recovery rate constant (kPCr), a measure of muscle oxidative capacity. The aim of this study was to investigate whether this kPCr gradient is related to O2 supply, resting phosphorylation potential, muscle fibre type, or type of exercise. Fifteen male volunteers performed continuous isometric ankle dorsiflexion at 30% maximum force until exhaustion. At multiple locations along the TA, we measured the oxidative PCr resynthesis rate (VPCr = kPCr × PCr depletion) by 31P MRS, the oxyhaemoglobin recovery rate constant (kO2Hb) by near infrared spectroscopy, and muscle perfusion with MR intravoxel incoherent motion imaging. The kO2Hb, kPCr, VPCr and muscle perfusion depended on measurement location (P < 0.001, P < 0.001, P = 0.032 and P = 0.003, respectively), all being greater proximally. The kO2Hb and muscle perfusion correlated with kPCr (r = 0.956 and r = 0.852, respectively) and VPCr (r = 0.932 and r = 0.985, respectively), the latter reflecting metabolic O2 consumption. Resting phosphorylation potential (PCr/inorganic phosphate) was also higher proximally (P < 0.001). The surrogate for fibre type, carnosine content measured by 1H MRS, did not differ between distal and proximal TA (P = 0.884). Performing intermittent exercise to avoid exercise ischaemia, still led to larger kPCr proximally than distally (P = 0.013). In conclusion, the spatial kPCr gradient is strongly associated with the spatial variation in O2 supply. It cannot be explained by exercise‐induced ischaemia nor by fibre type. Our findings suggest it is driven by a higher proximal intrinsic mitochondrial oxidative capacity, apparently to support contractile performance of the TA.

29 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BKBarbara Knäusl
Barbara Knäusl
FLFranciska Lebbink
Franciska Lebbink
PFPiero Fossati
Piero Fossati
EEErik Engwall
Erik Engwall
Dietmar GeorgDietmar Georg
Dietmar Georg
MSMarkus Stock
Markus Stock
Motion compensation strategies in particle therapy depend on the anatomy, motion amplitude and underlying beam delivery technology. This retrospective study on pancreas patients with small moving tumours analysed existing treatment concepts and serves as a basis for future treatment strategies for patients with larger motion amplitudes as well as the transition towards carbon ion treatments. The dose distributions of 17 hypofractionated proton treatment plans were analysed using 4D dose tracking (4DDT). The recalculation of clinical treatment plans employing robust optimisation for mitigating different organ fillings was performed on phased-based 4D computed tomography (4DCT) data considering the accelerator (pulsed scanned pencil beams delivered by a synchrotron) and the breathing-time structure. The analysis confirmed the robustness of the included treatment plans concerning the interplay of beam and organ motion. The median deterioration of D50% (ΔD50%) for the clinical target volume (CTV) and the planning target volume (PTV) was below 2%, while the only outlier was observed for ΔD98% with −35.1%. The average gamma pass rate over all treatment plans (2%/ 2 mm) was 88.8% ± 8.3, while treatment plans for motion amplitudes larger than 1 mm performed worse. For organs at risk (OARs), the median ΔD2% was below 3%, but for single patients, essential changes, e.g., up to 160% for the stomach were observed. The hypofractionated proton treatment for pancreas patients based on robust treatment plan optimisation and 2 to 4 horizontal and vertical beams showed to be robust against intra-fractional movements up to 3.7 mm. It could be demonstrated that the patient’s orientation did not influence the motion sensitivity. The identified outliers showed the need for continuous 4DDT calculations in clinical practice to identify patient cases with more significant deviations.

19 July 2023 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
FLFranciska Lebbink
Franciska Lebbink
SSSilvia Stocchiero
Silvia Stocchiero
PFPiero Fossati
Piero Fossati
EEErik Engwall
Erik Engwall
DGDietmar Georg
Dietmar Georg
BKBarbara Knäusl
Barbara Knäusl
• Parameter-based 4D dose calculation can quantify the interplay effect for small movers. • Inter-patient variability requires prospective 4D dose calculations in the clinic. • Measured dose difference of 0.1 Gy with a moving phantom compared to 4DDC. • Beam delivery dynamics did not influence the treatment robustness for motion <3 mm.

7 October 2026 in Physics in Medicine & Biology
Verified
Journal Article
Open access
MCMarisa Cobanaj
Marisa Cobanaj
FLFranciska Lebbink
Franciska Lebbink
SSSergej Schneider
Sergej Schneider
ESEmilia Louisa Ernestine Schäfer
Emilia Louisa Ernestine Schäfer
KPKrishna Godino Padre
Krishna Godino Padre
FHFelix Horst
Felix Horst
Objective. Integrating in-beam magnetic resonance imaging (MRI) with proton therapy (PT) introduces magnetic fields (MFs) that affect proton beam transport and therefore require accurate incorporation into the treatment planning system (TPS) for magnetic resonance (MR)-integrated PT (MRiPT). This study experimentally validates Monte Carlo-based proton dose calculation in the presence of the MF in a research version of the commercial TPS RayStation for MRiPT, using a measured three-dimensional (3D) magnetic vector field map of a 0.32 T in-beam MR scanner combined with a horizontal proton pencil beam scanning beam line. Approach. An MR-compatible mapping framework was used to acquire a high-resolution 3D magnetic vector field map, subsequently implemented into the TPS following coordinate transformations. Proton spot patterns and square radiation fields at 100, 150, and 220 MeV were delivered with and without the MF present. Dose distributions in air were measured using a 2D ionisation chamber array at multiple positions and compared with TPS dose calculations by analysing lateral beam shifts and field shape deformations with local γ -analysis. Clinically relevant patient treatment fields were evaluated at different water-equivalent depths (WEDs) in a phantom. Main results. Implementation of the measured magnetic vector field map preserved field vector magnitude, orientation and spatial alignment within the TPS. Dose measurements showed energy- and position-dependent MF-induced effects, which were accurately reproduced by the TPS. Agreement in lateral beam shifts was within 1–3 mm, and γ -pass rates exceeded 97% for a 3%/3 mm local criterion (10% dose threshold). Similar agreement was observed for patient treatment fields throughout all WEDs. Significance. This work validates the TPS capability to accurately model MF-induced proton beam transport in air as well as in a water-equivalent phantom. The present workflow establishes a foundation for proton treatment planning in the presence of MFs and thereby contributes to the clinical implementation of MRiPT.